Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation (VERIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03312712
Recruitment Status : Unknown
Verified January 2020 by Joseph Cheriyan, MD, Cambridge University Hospitals NHS Foundation Trust.
Recruitment status was:  Recruiting
First Posted : October 18, 2017
Last Update Posted : January 9, 2020
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Joseph Cheriyan, MD, Cambridge University Hospitals NHS Foundation Trust

Brief Summary:

The purpose of this study is to validate the method of analysing Positron Emission Tomography (PET) images to assess lung inflammation. Development of novel therapeutic drugs requires a biomarker which is sensitive to the underlying disease and can respond to therapeutic interventions. PET is a potential imaging biomarker which can target molecular and cellular processes. There is currently no standardised method of analysing PET lung data and a lack of validation for the existing techniques.

This study is divided in to two parts. Part A aims to determine the best method to perform 18F-FDG PET/CT lung analysis and how it correlates with cell counts from bronchoalveolar lavage (BAL) samples taken from participants with active pulmonary sarcoidosis.

Part B will compare imaging data from healthy volunteers who have either undergone a Lipopolysaccharide (LPS) challenge (whereby the lung is temporarily inflamed) or saline equivalent to determine whether lung inflammation can be detected by 18F-FDG PET/CT. No medications will be given and patients will not be asked to stop or change existing medication.


Condition or disease Intervention/treatment
Lung Inflammation Sarcoidosis Radiation: PET/CT scan Other: LPS Challenge Other: Saline Challenge Diagnostic Test: Blood and urine sampling

Detailed Description:

Inflammation plays an important role in a myriad of human diseases. Interstitial Lung Diseases (ILDs) are characterised by widespread inflammation and represent a major burden to the health sector. Imaging offers a method of assessing lung inflammation which is non-invasive and may help facilitate the development of new therapeutic drugs. Positron Emission Tomography (PET) is a sensitive imaging modality that uses radioactive material to highlight areas of disease. 18F-FDG is the most common radioactive tracer; it accumulates in cells with an increased metabolic rate. Previous studies have shown that inflammatory cells have an increased metabolic rate, thus PET imaging could highlight inflammation. 18F-FDG PET has been used in many studies exploring lung diseases; the concentration of tracer is thought to relate to the severity of inflammation.

There is currently no standardised method to analyse FDG-PET scans to assess the concentration of tracer in the lung (and therefore inflammation). A major challenge is providing corrections to ensure that the image only represents tracer in the lung tissue. Such corrections are non-trivial and affect how images are interpreted. A robust validation is needed to ensure that the analysis methods used in FDG-PET images truly represent the degree of lung inflammation.

Part A of this study aims to validate and compare the different analysis methods. Pulmonary sarcoidosis is a disease characterised by widespread lung inflammation. In Part A of the study the investigators will recruit patients with this condition, as well as age and gender matched (wherever possible) healthy volunteers. All Part A participants will receive one dynamic 18F-FDG PET/CT scan. The investigators will assess the uptake of 18FDG from PET images from patients with sarcoidosis versus those taken from healthy volunteers to validate and assess the reliability of the analysis method.

For Part B of the study the investigators will recruit healthy volunteers aged 50 or more. If sarcoidosis patients in Part A are 50 years old or more, the age-matched HV will be recruited in to Part B instead, thus potentially minimising the number of HVs that might need to be recruited in to Part A of the study.

The aims of this research study are:

i) To compare FDG-PET derived tissue inflammation measures against measures of inflammation from BAL samples.

ii) To compare different models of 18F-FDG lung analysis in patients with pulmonary sarcoidosis.

iii) To identify whether FDG PET is sensitive enough to detect a change in inflammation induced in healthy volunteers.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 36 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Validation of the Analysis Methodology Behind the Use of Quantitative 2-deoxy-2-[Fluorine-18] Fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Lung Inflammation
Actual Study Start Date : January 23, 2018
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Participants with sarcoidosis
  • Bronchoscopy, BAL collection, and PFTs* [SoC] *if required
  • Screening, research and safety bloods
  • Dynamic 18F-FDG PET/CT scan
Radiation: PET/CT scan

PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.

Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.

After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.

18F-FDG will be administered intravenously at a dose of approximately 200 MBq.

Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs.


Diagnostic Test: Blood and urine sampling
For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.

Healthy volunteers

Part A:

  • PFTs
  • Screening, research and safety bloods
  • Dynamic 18F-FDG PET/CT scan

Part B:

  • PFTs
  • Screening, research and safety bloods
  • Baseline and post challenge Dynamic 18F-FDG PET/CT scans
  • LPS/saline challenge
Radiation: PET/CT scan

PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.

Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.

After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.

18F-FDG will be administered intravenously at a dose of approximately 200 MBq.

Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs.


Other: LPS Challenge
In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.

Other: Saline Challenge
In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.

Diagnostic Test: Blood and urine sampling
For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.




Primary Outcome Measures :
  1. Validation of 18F-FDG methodology used to assess lung inflammation in participants with sarcoidosis [ Time Frame: Up to 4 weeks ]
    18F-FDG will be assessed using Patlak analysis and a compartmental model. This will be validated against histological samples from lung biopsies taken as part of the patient's standard clinical care prior to enrolling on to this study, and the inflammatory cell counts and densities (principally of macrophages and neutrophils) from BAL fluid in sarcoidosis patients.


Secondary Outcome Measures :
  1. Pulmonary function tests [ Time Frame: Screening Visit (V1) ]
    Spirometry (FVC and FEV1)

  2. Pulmonary function tests [ Time Frame: Screening Visit (V1) ]
    Gas transfer (TLCO measurement). Healthy volunteers will be asked to blow hard and fast into a mouthpiece for as long as possible and hold their breath for about 10 seconds.

  3. Plasma biomarkers of inflammation [ Time Frame: Up to 4 weeks ]
    CRP levels (mg/L)

  4. Plasma biomarkers of inflammation [ Time Frame: Up to 4 weeks ]
    Fibrinogen levels (mg/dL)

  5. Leukocyte count and activity from BAL fluid samples [ Time Frame: Up to 6 weeks ]
    Immunohistochemical staining where necessary (cell count)


Biospecimen Retention:   Samples Without DNA

Venous blood samples and Bronchoalveolar lavage (fluid taken as part of sarcoidosis patient standard of care bronchoscopy at Papworth Hospital) will be analysed at either Cambridge University Hospitals or Papworth Hospital.

Research specific venous blood and urine samples will be also obtained, where applicable, as per the study protocol for all participants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Cohort 1: Participants with suspected pulmonary sarcoidosis Cohort 2: Healthy volunteers who are non-smokers, age and gender matched, where possible, to cohort 1 participants
Criteria

For patients with sarcoidosis:

Inclusion Criteria:

  • Suspected pulmonary sarcoidosis (as determined by referring physician)
  • Requires bronchoscopy, EBUS and BAL (as determined by ILD team at Royal Papworth or Addenbrooke's Hospitals).
  • Male or female ≥ 30 years with a BMI of 17-35kg/m2
  • Consents to additional bronchoscopic evaluation during NHS mandated bronchoscopy, EBUS and BAL.

Exclusion Criteria:

  • Inability to provide Informed Consent.
  • A cardiovascular event in the last 6 months (i.e. acute coronary syndrome, unstable angina, CABG, PCI, stroke, MI, carotid endarterectomy).
  • Patients with known clinically significant pulmonary diagnoses of COPD, lung fibrosis, interstitial lung disease, or α1-antitrypsin deficiency.
  • Active smoking during the last 5 years.
  • Patients with known chronic infections such as HIV or known active tuberculosis.
  • Patients with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with active chronic inflammation (e.g. Inflammatory Bowel Disease).
  • Known diabetes mellitus or known impaired glucose tolerance
  • Participation in a previous research trial in the last three years which involved exposure to significant ionising radiation (i.e. cumulative research radiation dose >10 mSv)
  • Pregnancy
  • Women of childbearing potential [i.e. either postmenopausal or documented hysterectomy and/or bilateral oophorectomy - tubal ligation is not sufficient].
  • Use of systemic steroids (oral or intravenous) at a dose > 10mg od of prednisolone or equivalent and/or antibiotics 4 weeks prior to PET/CT scan
  • Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern

For healthy volunteers:

Inclusion criteria:

  • Age/gender-matched group (Part A only): Male or female ≥ 30 years with a BMI of 17-35kg/m2 inclusive
  • LPS/saline challenge group (Part B only): Male or female ≥ 50 years with a BMI of 17-35kg/m2 inclusive
  • No smoking history
  • Normal predicted spirometry values: FEV1/FVC > 0.7 and FEV1 > 80% predicted
  • Healthy as determined by clinical history & examination by the investigator

Exclusion criteria:

  • Inability to provide informed consent
  • Pregnancy
  • Patients with known chronic inflammation conditions such as rheumatoid arthritis, connective tissue disorders and inflammatory bowel disease
  • A significant cardiovascular event in the last 6 months
  • Insulin dependent diabetes mellitus or known impaired glucose tolerance
  • Participation in previous research trial in the last three years which involves exposure to significant ionising radiation (cumulative dose >10mSv)
  • Use of systemic steroids (oral or intravenous) at a dose > 10mg od of prednisolone or equivalent and/or antibiotics 4 weeks prior to PET/CT scan
  • Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern
  • Women of childbearing potential
  • Patients with known chronic infections such as HIV or known active tuberculosis.
  • Active smoking history (defined as > than 1 cigarette per day on a regular basis) over lifetime
  • Known lung and/or respiratory disease or associated symptoms (e.g. dyspnoea, wheeze)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03312712


Contacts
Layout table for location contacts
Contact: Laurence Vass 01223 216895 ldv22@cam.ac.uk

Locations
Layout table for location information
United Kingdom
Cambridge University Hospitals NHS Foundation Trust Recruiting
Cambridge, United Kingdom, CB2 0QQ
Contact: Laurence Vass, MSc         
Principal Investigator: Joseph Cheriyan, MBCHB, MA, FRCP         
Sub-Investigator: Omar Mukhtar, MB, ChB, BSc, MRCP         
Sub-Investigator: Laurence Vass, MSc         
Royal Papworth Hospital NHS Foundation Trust Recruiting
Papworth Everard, United Kingdom, CB23 3RE
Contact: Muhunthan Thillai, BA, PhD, MRCP         
Principal Investigator: Muhunthan Thillai, BA, PhD, MRCP         
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline
Investigators
Layout table for investigator information
Principal Investigator: Joseph Cheriyan, MBChB, MA, FRCP Cambridge University Hospitals NHS Foundation Trust
Layout table for additonal information
Responsible Party: Joseph Cheriyan, MD, Consultant Clinical Pharmacologist & Physician/Associate Lecturer, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT03312712    
Other Study ID Numbers: VERIFY
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: January 9, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Joseph Cheriyan, MD, Cambridge University Hospitals NHS Foundation Trust:
FDG
PET
CT
Sarcoidosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Sarcoidosis
Inflammation
Pathologic Processes
Lymphoproliferative Disorders
Lymphatic Diseases
Hypersensitivity, Delayed
Hypersensitivity
Immune System Diseases
Respiratory Tract Infections
Infections
Lung Diseases
Respiratory Tract Diseases